Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the receipt of $5 million from Nycomed for reaching a clinical milestone under the license and collaboration agreement, entered into on July 11, 2008.

26 May 2010

Biogen Idec to join global MS community to commemorate the second annual World MS Day

On May 26, Biogen Idec will join the global multiple sclerosis community to commemorate the second annual World MS Day. Biogen Idec is a leader in the fight against MS, bringing hope to the thousands of patients across the globe who benefit from the company's MS therapies and ongoing research programs.

25 May 2010

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

Biogen Idec and Abbott today announced enrollment of the first patient in a global Phase III study evaluating the efficacy and safety of daclizumab compared to interferon beta-1a (AVONEX®) in patients with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS).

25 May 2010

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Agilent Technologies Inc. today introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

25 May 2010

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen Corporation announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation to RG2833, a selective histone deacetylase 3 inhibitor for the treatment of Friedreich's ataxia. Orphan drug designation qualifies Repligen to receive seven years of marketing exclusivity in the United States if the company is the first to obtain marketing approval for RG2833 for the treatment of Friedreich's ataxia.

24 May 2010

Immunome announces completion of financing by BioAdvance

Immunome, a discovery-stage antibody platform company focused on life-threatening infectious diseases, announced today the completion of a financing by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. The funding round also included private investors.

24 May 2010

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that they have completed enrollment of a phase II clinical trial of brentuximab vedotin (SGN-35) for relapsed or refractory systemic anaplastic large cell lymphoma.

24 May 2010

2010 ASCO Annual Meeting highlights new research findings on cancer

Experts from The Cancer Institute at NYU Langone Medical Center will present new research findings at the 46th Annual Meeting of The American Society of Clinical Oncology (ASCO) in Chicago, Illinois.

24 May 2010

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that updates on several of its BiTE antibody development programs will be made at two upcoming medical conferences.

21 May 2010

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

ImmunoCellular Therapeutics, Ltd. a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that it will be presenting results from its clinical trial of ICT-107 at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8 in Chicago.

21 May 2010

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company today announced that data regarding retreatment experiences with brentuximab vedotin in phase I and phase II clinical trials will be presented during a poster session at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.

21 May 2010

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced financial and operational results for the fiscal year ended January 31, 2010.

20 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

PET scanning provides great insight into immune response

A commonly used probe for Positron Emission Tomography scanning and a new probe developed by researchers at UCLA reveal different functions in diverse cells of the immune system, providing a non-invasive and much clearer picture of an immune response in action.

19 May 2010

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

ImmunoCellular Therapeutics, a clinical-stage biotechnology company that is developing immune based therapies for the treatment of brain and other cancers, announced today that the Company and Torrey Pines Institute for Molecular Studies in San Diego, CA have identified several peptides which can generate CD-133 specific T-cells. CD-133 is found in high abundance on cancer stem cells ("CSCs") which makes it promising for immunological targeting.

18 May 2010

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.

18 May 2010

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), reversed the process of fibrosis in a preclinical model of radiation-induced lung fibrosis, a finding that has implications for treating multiple types of fibrotic disease.

18 May 2010

Monoclonal Antibody News and Research

Further Reading

Immunomedics announces receipt of $5M from Nycomed for reaching clinical milestone

Biogen Idec to join global MS community to commemorate the second annual World MS Day

Biogen Idec, Abbott commence enrollment in Phase III comparative study of daclizumab to AVONEX for RRMS

New HPLC-Chip introduced to address N-glycan analysis in biopharmaceutical market

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Immunome announces completion of financing by BioAdvance

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

2010 ASCO Annual Meeting highlights new research findings on cancer

Updates on Micromet's BiTE antibody development programs to be made at two medical conferences

ImmunoCellular Therapeutics to present clinical results of ICT-107 dendritic cell immunotherapy at 46th ASCO

Data on retreatment experiences with brentuximab vedotin in clinical trials to be presented at 2010 ASCO

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

ZymoGenetics' IL-21 Phase 2 trial data in metastatic melanoma to be presented at ASCO annual meeting

Quest PharmaTech net consolidated loss for 2010 increases to $517,799

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

PET scanning provides great insight into immune response

IMUC, Torrey Pines Institute identify peptides that generate CD-133 specific T-cells

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

FibroGen's FG-3019 human monoclonal antibody against CTGF reverses progression of lung fibrosis

Immunology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News